Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days (Q33368966)

26 July 2017

title

Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days (English)

1 reference

26 July 2017

1 reference

1 reference

Yasuhide Yamada

1

1 reference

26 July 2017

Noboru Yamamoto

2

1 reference

26 July 2017

Tatsu Shimoyama

3

1 reference

26 July 2017

Atsushi Horiike

4

1 reference

26 July 2017

Yasuhito Fujisaka

5

1 reference

26 July 2017

Kyoko Takayama

6

1 reference

26 July 2017

Terumi Sakamoto

7

1 reference

26 July 2017

Yuki Nishioka

8

1 reference

26 July 2017

Sanae Yasuda

9

1 reference

26 July 2017

Tomohide Tamura

10

1 reference

26 July 2017

language of work or name

1 reference

1 October 2005

1 reference

26 July 2017

1 reference

26 July 2017

volume

96

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

721-728

1 reference

Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00109.X

E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00109.X

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00109.X

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00109.X

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00109.X

Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00109.X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00109.X

In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2005.00109.X

10.1111/J.1349-7006.2005.00109.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference